Standout Papers
Citation Impact
Citing Papers
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
2009 Standout
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
2007 StandoutScience
Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)
2009 Standout
Pharmacokinetics of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors: the Role of Alpha-1-Acid Glycoprotein Binding
2011
Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality
2020 StandoutNobel
Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor
2008
PD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
2019 StandoutNobel
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
2017 StandoutNature
Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma
2012 Standout
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
2009 Standout
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients
1999 Standout
Oncology Meets Immunology: The Cancer-Immunity Cycle
2013 Standout
Gastrointestinal stromal tumour
2007
The role of KIT in the management of patients with gastrointestinal stromal tumors
2007
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Translating cancer research into targeted therapeutics
2010 Nature
Beyond Imatinib: Second Generation c-KIT Inhibitors for the Management of Gastrointestinal Stromal Tumors
2006
Results of Tyrosine Kinase Inhibitor Therapy Followed by Surgical Resection for Metastatic Gastrointestinal Stromal Tumor
2007
Oncomine 3.0: Genes, Pathways, and Networks in a Collection of 18,000 Cancer Gene Expression Profiles
2007 Standout
Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias
2006 Standout
Immunogenic cell death in cancer and infectious disease
2016 Standout
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
2011 Standout
Cancer stem cells revisited
2017 Standout
Inducers of immunogenic cancer cell death
2013
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours
2006
Chemoimmunotherapy: reengineering tumor immunity
2013
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
2006 Standout
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
2010 StandoutNature
The landscape of long noncoding RNAs in the human transcriptome
2015 Standout
Antibody therapy of cancer
2012 Standout
Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: Analyis of EORTC-ISG-AGITG study 62005
2007
Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance
2013
Synthetic lethality as an engine for cancer drug target discovery
2019
Drug Insight: gastrointestinal stromal tumors (GIST)—the solid tumor model for cancer-specific treatment
2008
Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800mg after progression on 400mg
2005
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
2009
Gut microbiota modulation of chemotherapy efficacy and toxicity
2017 Standout
Epigenetic treatment of solid tumours: a review of clinical trials
2015
Translation of new cancer treatments from pet dogs to humans
2008 Standout
Regulatory T cells in cancer immunotherapy
2016 StandoutNobel
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy
2017 Standout
VEGF-targeted therapy: mechanisms of anti-tumour activity
2008 Standout
Benefit-Risk Assessment of Sunitinib in Gastrointestinal Stromal Tumours and Renal Cancer
2009
Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas
2009
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
2010 Standout
Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas
2009
Clinical pharmacokinetics of tyrosine kinase inhibitors
2009
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
2017 Standout
The secret ally: immunostimulation by anticancer drugs
2012
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
2011 StandoutNobel
Combination raltitrexed (Tomudex®)–oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma
2000
Gastrointestinal Stromal Tumors
2005
The Clavien-Dindo Classification of Surgical Complications
2009 Standout
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
2016 Standout
NF-κB, inflammation, immunity and cancer: coming of age
2018 Standout
The cancer genome
2009 StandoutNature
Immunogenic cell death and DAMPs in cancer therapy
2012 Standout
HIF activation causes synthetic lethality between the VHL tumor suppressor and the EZH1 histone methyltransferase
2017 StandoutNobel
Regulatory T-cell Modulation Using Cyclophosphamide in Vaccine Approaches: A Current Perspective
2012
The role of the microbiota in inflammation, carcinogenesis, and cancer therapy
2014
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
2014 Standout
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
2003 Standout
Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies
2017 StandoutNobel
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
2013 Standout
Prospective Multicentric Randomized Phase III Study of Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors Comparing Interruption Versus Continuation of Treatment Beyond 1 Year: The French Sarcoma Group
2007
Sunitinib: From Rational Design to Clinical Efficacy
2007
Using Single-Agent Therapy in Adult Patients with Advanced Soft Tissue Sarcoma Can Still Be Considered Standard Care
2005
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
2016 Standout
Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033
2008
Natural Killer Cell IFN-γ Levels Predict Long-term Survival with Imatinib Mesylate Therapy in Gastrointestinal Stromal Tumor–Bearing Patients
2009
Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors
2006
A New Initiative on Precision Medicine
2015 Standout
Imatinib Mesylate in Advanced Dermatofibrosarcoma Protuberans: Pooled Analysis of Two Phase II Clinical Trials
2010
Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation
2005
Liquid Biopsies: Genotyping Circulating Tumor DNA
2014 Standout
WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs
2019 Standout
Approval Summary: Sunitinib for the Treatment of Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors and Advanced Renal Cell Carcinoma
2007
Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity
2017 StandoutNobel
Immunogenic Cell Death in Cancer Therapy
2012 Standout
Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression
2012
Works of A. Lecesne being referenced
Cyclophosphamide Induces Differentiation of Th17 Cells in Cancer Patients
2010
A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group
2013
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial
2004 Standout
Population Pharmacokinetics and Pharmacogenetics of Imatinib in Children and Adults
2008
Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas
2001
Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results.
1995